Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

715
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
715
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

769
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
769

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving beyond anatomy: the future of rectal cancer management is biologically-informed, response-adapted, and patient-centered.

Clinical and translational radiation oncology·2026
Same author

Needle-track metastasis in diffuse intrinsic pontine glioma: Need for a standardized surgical strategy?

Neuro-oncology advances·2026
Same author

Dose-de-escalated focal radiotherapy for primary cutaneous T-cell lymphoma: a lesion-based retrospective cohort study.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Prognostic value of DICER and CA9 expression in patients with anal squamous cell carcinoma treated with definitive chemoradiotherapy.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Intra-arterial chemoperfusion for breast cancer brain metastases: safety and efficacy.

Neuroradiology·2026
Same author

[Neoadjuvant chemotherapy versus chemoradiotherapy in rectal cancer without involvement of the mesorectal fascia-Implications of CONVERT for radiation oncology?]

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Related Experiment Video

Updated: Mar 14, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.9K

Rectal cancer: Neoadjuvant chemoradiotherapy.

Claus Rödel1, Ralf Hofheinz2, Emmanouil Fokas3

  • 1Department of Radiotherapy and Oncology, University of Frankfurt, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK) Partner Site: Frankfurt, Germany.

Best Practice & Research. Clinical Gastroenterology
|September 21, 2016
PubMed
Summary

Adding oxaliplatin to preoperative chemoradiotherapy for rectal cancer did not improve outcomes in most trials. Future rectal cancer treatments will be risk-adapted, considering individual patient factors.

Keywords:
ChemoradiotherapyInduction and consolidation chemotherapyNovel trialsOrgan preservationRectal cancerTargeted agents

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.4K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

988

Related Experiment Videos

Last Updated: Mar 14, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.9K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.4K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

988

Area of Science:

  • Oncology
  • Gastrointestinal Surgery
  • Radiation Oncology

Background:

  • The standard preoperative chemoradiotherapy (CRT) for rectal cancer may not be optimal for all patients.
  • The addition of oxaliplatin to CRT is being investigated for improved efficacy.

Purpose of the Study:

  • To evaluate the efficacy of adding oxaliplatin to preoperative 5-fluorouracil (5-FU) or capecitabine-based CRT in rectal cancer.
  • To review novel treatment strategies for rectal cancer.

Main Methods:

  • Analysis of five randomized trials comparing CRT with or without oxaliplatin.
  • Review of phase II trials investigating cetuximab and VEGF inhibition with CRT.
  • Examination of ongoing clinical trials exploring induction/consolidation chemotherapy, de-escalated surgery, and radiotherapy omission.

Main Results:

  • Four out of five randomized trials showed no significant benefit in early or late efficacy endpoints with the addition of oxaliplatin.
  • Phase II trials with cetuximab demonstrated low pathological complete response (pCR) rates.
  • CRT with VEGF inhibition showed promising pCR but increased surgical complications.

Conclusions:

  • The addition of oxaliplatin to standard preoperative CRT for rectal cancer (TNM stage II/III) does not consistently improve outcomes.
  • Future rectal cancer management should adopt risk-adapted multimodal treatment strategies tailored to individual patient and tumor characteristics.
  • Emerging strategies include induction/consolidation chemotherapy, de-escalated surgery, and selective omission of radiotherapy.